61 A working core outcome set for CLE trials was recently developed to guide future clinical and outcomes research in CLE, recommending the CLASI as a primary endpoint and the Cutaneous Lupus Activity IGA (CLA-IGA) as a secondary endpoint for CLE physician-reported outcome measures
Myth: More ingredients = better results. Fact: More ingredients can also mean more variables (tolerability, interactions, unclear dosing)
At most concentrations, it delivers an intermediate dose
GLP-1 plays into this communication system
Contains no synthetic colors, flavors, or preservatives
3X the benefits: Semaglutide (Ozempic and Wegovy) gained immense popularity for its ability to provide weight loss, reduced appetite, and stabilized insulin release, for sustained weight loss